In the realm of biopharma and biotech, the integration of data and science is paramount to addressing the multifaceted challenges presented by modern processes. These industries are awash with data from various sources, including experimental results, patient records, and sensor data. Traditional methods of data analysis, whether purely mechanistic or purely data-driven, can fall short in capturing the full complexity of these datasets. By integrating data and scientific principles, hybrid modelling offers a robust framework that leverages the strengths of both approaches to provide deeper insights and more accurate predictions
Mechanistic models, grounded in the fundamental laws of physics, chemistry, and biology, offer a structured way to describe processes based on known scientific principles. These models are invaluable for their ability to explain the underlying mechanisms of a system. However, they often require extensive domain knowledge and may not capture all the variability present in real-world data. On the other hand, data-driven models, such as those powered by machine learning, excel at identifying patterns and correlations within large datasets without requiring explicit knowledge of the underlying processes. The synergy of these two approaches in hybrid modelling allows for the construction of models that are both explanatory and predictive.
The integration of data and science through hybrid modelling is particularly crucial in the context of biopharma and biotech industries, where the stakes are high, and the timelines for developing new treatments and technologies are often compressed. By combining the explanatory power of mechanistic models with the predictive prowess of data-driven models, hybrid modelling can accelerate the development process, optimize resource allocation, and improve decision-making. This integrated approach not only enhances the accuracy and robustness of models but also provides a scalable solution to manage the increasing complexity of biopharma and biotech processes.
Mechanistic models offer interpretability and scientific rigor but often require simplifying assumptions and extensive parameter estimation. On the other hand, data-driven models excel at capturing nonlinear patterns but may lack extrapolation capability and scientific explainability—especially when data is limited or operating conditions change.
In real-world bioprocessing, neither approach alone is sufficient.
Hybrid modelling addresses this gap by embedding scientific understanding into data-driven frameworks, ensuring models remain both predictive and physically meaningful.
Hybrid models perform reliably across lab, pilot, and manufacturing scales, reducing surprises during scale-up and tech transfer.
By leveraging both data and science, teams can reduce experimental iterations, saving time and cost.
Hybrid models provide actionable insights while retaining interpretability—critical for regulatory confidence and internal alignment.
They handle process disturbances, raw material variability, and operating changes more effectively than standalone models.
Despite advances in automation and analytics, manufacturers across these industries continue to face recurring challenges, including:
Hybrid modelling is specifically designed to address these issues in a systematic and technically rigorous manner.
Traditional scale-up approaches often rely on empirical rules or simplified assumptions that break down at larger scales. Hybrid modelling mitigates this by:
This leads to improved predictive reliability across laboratory, pilot, and commercial scales.
Variability is a defining characteristic of biologics and specialty chemical processes. Common sources include raw material variability, biological heterogeneity, and time-varying kinetics. Hybrid modelling enables:
As a result, manufacturers achieve more consistent yields and quality attributes.
Many critical states and quality attributes cannot be measured in real time due to technical or economic constraints. Hybrid modelling supports:
This significantly improves process transparency and operational confidence.
Pharma, biotech, and chemical processes are typically multivariable, constrained, and strongly nonlinear, limiting the effectiveness of classical control strategies. Hybrid models, when deployed within digital twin and model predictive control (MPC) frameworks, enable:
This leads to sustained improvements in productivity, yield, and energy efficiency.
Regulatory frameworks increasingly emphasize mechanistic understanding and scientifically justified control strategies. Hybrid modelling directly supports QbD and PAT initiatives by:
This reduces regulatory risk while strengthening process understanding.
Hybrid modelling forms the computational core of industrial digital twins, enabling:
Organizations adopting hybrid modelling consistently realize:
Hybrid modelling represents a shift from empirical, trial-and-error optimization toward science-guided, data-augmented intelligence across the entire manufacturing lifecycle.
Hybrid modelling is not just a modelling technique - it’s a step toward intelligent, adaptive processing. When integrated with real-time data and advanced analytics, hybrid models enable proactive control, predictive monitoring, and continuous improvement.
Organizations that adopt this approach early gain a competitive edge through faster development, higher robustness, and smarter decision-making.
To gain a deeper, application-focused understanding of how hybrid modelling is implemented in real industrial environments, we invite you to our 2-part technical webinar series on Hybrid Modelling.